Newsletters

[Nature Communications] Researchers revealed that early mitochondrial reprogramming, characterized by the activation of oxidative phosphorylation, is a determinant of differentiation initiation.

[Proceedings of the National Academy of Sciences of the United States of America] Scientists identified a previously unrecognized RNA-based mechanism that maintains pathogenic fibroblast states during skin fibrosis.

[Advanced Healthcare Materials] Investigators presented a 3D embedded bioprinting strategy for engineering vascularized biopatches through the precise integration of prevascularized multicellular spheroids within a skin-derived decellularized extracellular matrix bioink.

[Cell Death Discovery] Researchers showed that CaMK4 was highly expressed in CD4⁺ T cells from psoriatic lesional skin in both humans and mice.

[European Archives of Oto-Rhino-Laryngology] Scientists examined the role of PAI-1 plays in the pathophysiology of cholesteatoma and investigated how TGF-β1 and PAI-1 interact to regulate keratinocyte proliferation.

[Molecular Carcinogenesis] The authors identified novel molecular targets associated with melanoma progression. Consensus clustering analysis revealed three melanoma subtypes, with the C3 subtype exhibiting the worst prognosis.

[Cellular Signalling] Using single-cell RNA sequencing in a B16 melanoma model, researchers identified a metastasis-enriched endoplasmic reticulum-stress tumor state characterized by increased Xbp1 regulon activity.

[International Journal of Stem Cells] Scientists summarizes the recent advances in melanoma genetically engineered mouse models, highlights the oncogenic signaling pathways active in these systems, and discusses the molecular insights derived from these models regarding melanoma initiation, progression, and intratumoral diversity.

[Moffitt Cancer Center ] New research from Phase III trial finds personalized intismeran plus pembrolizumab may better prevent high-risk melanoma recurrence after surgery.

[Cellenkos, Inc. (PR Newswire)] Cellenkos, Inc. announced that the US FDA has granted Fast Track designation to CK0803 for the treatment of Amyotrophic Lateral Sclerosis (ALS). CK0803 is an investigational, allogeneic, cord blood-derived Treg cell therapy engineered to express high levels of CXCR3 and CD11a.

[Immunity] Researchers compared ovalbumin (OVA)-specific T cell fates using mice fed OVA, or expressing secreted, cytosolic (c), or transmembrane epithelial OVA. BATF3+ antigen-presenting cells were indispensable for CD4+ T cell proliferation only in cOVA mice, yet they drove Treg cell differentiation across all epithelial OVA models.

[EMBO Journal] Investigators showed that agonistic anti-CD137 monoclonal antibodies target multiple CD137-expressing cell types, including activated CD8⁺ T-cells, Tregs, follicular Tregs, and follicular dendritic cells.